Formulating a highly lipophilic and poorly soluble crystalline molecule, such as cannabidiol (CBD), can be a complex task. In fact, the oral bioavailability of CBD can be as low as 6% in humans, as a result of incomplete absorption in the gut and significant pre-systemic elimination in the liver.1
This has slowed the development of patient-friendly solid oral dosage forms—until now.
CBtru®, a novel drug delivery solution, is opening a new era in drug formulation. One that helps unlock the full potential of highly lipophilic molecules, such as cannabidiol (CBD). By optimizing bioavailability in solid oral dosage forms, CBtru® supports more patient-friendly delivery options, including tablets and capsules. The result: elevated patient care through improved convenience and adherence.
Make oral solid dosage forms a reality—supporting enhanced patient-centricity and wider applicability.
Harness three to four times higher API loading to achieve lower daily dosages and more convenience for patients.
CBtru® has a comparable bioavailability to the only market-approved CBD drug product, which is a liquid oil-based dosage form.
Clinical research confirms that CBtru® is safe and well-tolerated in humans.
New clinical research validates that our first-of-a-kind CBD drug product intermediate, CBtru®, offers optimized bioavailability in oral solid dosage forms, which is as good as the current gold-standard liquid oil-based CBD medicine. Plus, it may offer a more reliable and consistent uptake, less dependent on food intake.
Discover how we joined forces with Oz Medicann Group (OMG) Pharma–-an Australian-based biotech innovator in the cannabinoid medicines domain—to create a CBD-based oral solid dosage form using CBtru®. Together, we pioneer patient-friendly orally disintegrating tablets (ODTs) for the treatment of insomnia.
Discover how dsm-firmenich and Bayer reduced vitamin C’s carbon footprint by 49% through renewable energy, process innovation, and sustainable pharma collaboration.
Discover how dsm-firmenich is tackling the challenge of bitter medicine with a receptor-based technology designed to elevate drug palatability and improve patient adherence.
Explore how dsm-firmenich can help pharma raise the bar in patient-centricity and sustainability.
1. Perucca and Bialer. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. Cannabinoids in Neurology and Psychiatry, 2020.
2. Millar et al. Towards better delivery of cannabidiol (CBD). Pharmaceuticals (Basel), vol. 13, pg. 219, 2020.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.